Inactive Instrument

ME RESO Stock

Equities

MEC

CA5527491032

Dynamic Chart
ME Resource Corp. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Albert Labs Inc. completed the acquisition of ME Resource Corp. in a reverse merger transaction. CI
ME Resource Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Me Resource Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
ME Resource Corp. Reports Earnings Results for the First quarter Ended March 31, 2021 CI
Me Resource Corp. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Albert Labs Inc. entered into a letter of intent to acquire ME Resource Corp. in a reverse merger transaction. CI
Me Resource Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Me Resource Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Me Resource Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
ME Resource Corp. Auditor Raises 'Going Concern' Doubt CI
Me Resource Corp. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Me Resource Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Me Resource Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Me Resource Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
More news
Albert Labs International Corp., formerly ME Resource Corp., is a Canada-based psychedelics company. The Company is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The Company focuses on treating patients with urgent and unmet mental health needs, starting with cancer-related anxiety. It is also focused on improving patient access to psychedelic-assisted therapies. The Company has an asset-light business model, leveraging existing clinical infrastructure and patient pools by collaborating with research institutions, medical centers and reimbursement networks. The Company uses an accelerated pathway, Real-World Evidence (RWE) studies, to provide access to patients in need. It also provides in-house lab results in formulation.
Sector
-
More about the company